[Skip to Content]
[Skip to Content Landing]
January 17, 1966

Long Range Chemotherapy for Heart Attacks

Author Affiliations

Mount Vernon, NY

JAMA. 1966;195(3):228. doi:10.1001/jama.1966.03100030122041

To the Editor:—  One cannot deny the proper intentions of the longrange study1 under the sponsorship of the government's National Institutes of Health to determine the effectiveness of various drugs in reducing subsequent coronary heart attacks in subjects with histories of one or more. The program has been labeled ambitious, which it is indeed. Though costly and time consuming, the need for a form of therapy to prevent or even reduce cardiovascular catastrophies is recognized by the world medical community.However, serious consideration must be given to the preparation of the protocol for this vast undertaking. After five or seven years, the validity of the results may be applied only to the hypothesis, "Chemotherapy does or does not reduce the number of coronary heart attacks or deaths in a selected group of patients who have had one or more previous coronary catastrophies."1 Morphological vascular regression, arrest, or progression

First Page Preview View Large
First page PDF preview
First page PDF preview